PPARδ agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-26 and is reviewed periodically as new material appears.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
At WrestleMania 13, Hart defeated Austin in a highly acclaimed submission match with Ken Shamrock as a special referee. During the match, Hart and Austin made a double turn, changing Austin to babyface. Austin portrayed an anti-hero instead of a traditional babyface. Austin's public popularity surged following the Wrestlemania clash, and Austin 3:16 merchandise t-shirts were reported in May 1997 to have become the best-selling WWF t-shirts since Hulkamania. Austin eventually got his revenge on Hart in the main event of In Your House 14: Revenge of the 'Taker, defeating him in a match to determine the next contender to The Undertaker's WWF Championship. Austin won when Hart was disqualified due to assistance from The British Bulldog. At In Your House 15: A Cold Day in Hell, Austin had The Undertaker down with the Stone Cold Stunner but was distracted by Pillman, allowing The Undertaker to recover and perform a Tombstone Piledriver for the victory. Austin won the WWF Tag Team Championship twice: first with Shawn Michaels, who vacated the title due to an injury, and with Dude Love. Austin also feuded with Owen Hart, facing him during a ten-man Tag Team match at In Your House 16: Canadian Stampede. At SummerSlam 1997, Austin defeated Owen for the Intercontinental Championship. During the match, Owen botched a Sit-out Piledriver and dropped Austin on his head, resulting in a legitimate bruised spinal cord and temporary paralysis for Austin. Due to the severity of his neck injury, Austin was forced to relinquish both championships.
Kinship is seen as the basis of organized crime rather than the structures Cressey had identified; this includes fictive godparental and affinitive ties as well as those based on blood relations and it is the impersonal actions, not the status or affiliations of their members, that define the group. Rules of conduct and behavioral aspects of power and networks and roles include the following:
== Acquisitions == 2000: Icon acquired UK-based regulatory consultancy, YRCR Ltd.; Central Laboratory in New York; and bioanalytical consultancy, Pacific Research 2002: Icon acquired clinical research provider, BPA. 2003: Icon acquired Medieval, a UK-based Phase I facility, and US consulting firm, Globomax 2004: Icon acquired medical imaging specialist, Beacon Bioscience Inc. 2006: Icon acquired outcomes research and health economics specialist, Ovation Research Group 2007: Icon acquired European staffing group, DOCS International 2008: Icon acquired US phase I provider, Healthcare Discoveries and US bioanalytical lab, Prevalere Life Sciences 2009: Icon acquired Veeda Laboratories, a UK biomarker lab 2010: Icon acquired Timaq Medical Imaging Inc.
=== Coupling CE with MALDI-MS === Off-line coupling of CE to MALDI, the CE effluent could be sprayed or added drop wise on MALDI target plate then dried and analyzed by MS. For online coupling, a moving target with continuous contact to CE capillary end is required. The moving target takes analytes into MS where it is desorbed and ionized. Musyimi et al. developed a new technique where rotating ball was used to transfer CE to MS. The sample from CE is mixed with matrix coming though another capillary. As the ball rotates the sample is dried before it reaches ionization region. This technique has high sensitivity since no makeup fluid is used.
Sources: en.wikipedia.org
The BAFTA Games Awards or British Academy Games Awards are an annual British awards ceremony honouring "outstanding creative achievement" in the video game industry. First presented in 2004 following the restructuring of the BAFTA Interactive Entertainment Awards, the awards are presented by the British Academy of Film and Television Arts (BAFTA). Since the inaugural BAFTA Games Awards in February 2004, twenty-two ceremonies have taken place. The most recent, the 22nd British Academy Games Awards, were held at the Queen Elizabeth Hall on 17 April 2026.
MCAS is generally considered a diagnosis of exclusion, meaning that other potential diagnoses must be ruled out before it is applied. Given a diagnosis of MCAS as described above, various subclassifications of MCAS have been proposed depending on the presence of specific pathologies or triggers. MCAS may be considered primary (if KIT genetic mutations or clonal MCs in bone marrow are detected), secondary (if IgE-mediated or non-IgE-mediated allergy mechanisms are present), combined (involving multiple variants), or idiopathic (if specific causes cannot be identified). There is debate over whether HαT, a genetic trait involving copies of the TPSAB1 gene which encodes for alpha-tryptase, should be considered a modifying factor that influences mediator-related symptoms or an initiator for a subcategory of MCAS.
Over the first three-quarters of the 19th century, many experimenters worked with various combinations of platinum or iridium wires, carbon rods, and evacuated or semi-evacuated enclosures. Many of these devices were demonstrated and some were patented. In 1835, James Bowman Lindsay demonstrated a constant electric light at a public meeting in Dundee, Scotland. He stated that he could "read a book at a distance of one and a half feet". However he did not develop the electric light any further. In 1838, Belgian lithographer Marcellin Jobard invented an incandescent light bulb with a vacuum atmosphere using a carbon filament. In 1840, British scientist Warren De la Rue enclosed a coiled platinum filament in a vacuum tube and passed an electric current through it. The design was based on the concept that the high melting point of platinum would allow it to operate at high temperatures and that the evacuated chamber would contain fewer gas molecules to react with the platinum, improving its longevity. Although a workable design, the cost of the platinum made it impractical for commercial use. In 1841, Frederick de Moleyns of England was granted the first patent for an incandescent lamp, with a design using platinum wires contained within a vacuum bulb. He also used carbon. In 1845, American John W. Starr patented an incandescent light bulb using carbon filaments. His invention was never produced commercially. In 1851, Jean Eugène Robert-Houdin publicly demonstrated incandescent light bulbs on his estate in Blois, France.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.